GRAIL (NASDAQ:GRAL) Price Target Raised to $75.00

GRAIL (NASDAQ:GRAL) had its target price raised by Canaccord Genuity Group from $43.00 to $75.00 in a report issued on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, UBS Group set a $75.00 price objective on GRAIL in a report on Friday. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $56.67.

GRAIL Stock Performance

Shares of NASDAQ GRAL opened at $65.54 on Friday. The business’s 50 day moving average price is $38.69 and its 200-day moving average price is $37.12. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -5.00 and a beta of 4.11. GRAIL has a fifty-two week low of $12.33 and a fifty-two week high of $73.74.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing the consensus estimate of ($3.14) by ($0.04). The firm had revenue of $35.54 million for the quarter, compared to analysts’ expectations of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. Sell-side analysts predict that GRAIL will post -15.15 earnings per share for the current year.

Insider Buying and Selling at GRAIL

In other GRAIL news, President Joshua J. Ofman sold 9,692 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $64.00, for a total transaction of $620,288.00. Following the sale, the president owned 478,182 shares of the company’s stock, valued at approximately $30,603,648. This trade represents a 1.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Aaron Freidin sold 8,000 shares of the stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $38.93, for a total value of $311,440.00. Following the sale, the chief financial officer directly owned 286,020 shares in the company, valued at $11,134,758.60. This trade represents a 2.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,894 shares of company stock worth $1,066,276 in the last ninety days. Insiders own 1.85% of the company’s stock.

Institutional Trading of GRAIL

Institutional investors have recently made changes to their positions in the business. Caldwell Sutter Capital Inc. acquired a new stake in shares of GRAIL in the 1st quarter worth $28,000. KBC Group NV boosted its position in shares of GRAIL by 187.7% in the 1st quarter. KBC Group NV now owns 1,430 shares of the company’s stock worth $37,000 after purchasing an additional 933 shares in the last quarter. S.A. Mason LLC boosted its position in shares of GRAIL by 50.1% in the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company’s stock worth $38,000 after purchasing an additional 500 shares in the last quarter. Farther Finance Advisors LLC lifted its position in GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $42,000 after acquiring an additional 722 shares during the period. Finally, NewEdge Advisors LLC lifted its position in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after acquiring an additional 1,401 shares during the period.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.